Last reviewed · How we verify
CT-P53
CT-P53 is a monoclonal antibody that binds to and inhibits programmed death ligand 1 (PD-L1), blocking its interaction with PD-1 and restoring anti-tumor immune responses.
CT-P53 is a monoclonal antibody that binds to and inhibits programmed death ligand 1 (PD-L1), blocking its interaction with PD-1 and restoring anti-tumor immune responses. Used for Non-small cell lung cancer, Other solid tumors (under investigation in Phase 3).
At a glance
| Generic name | CT-P53 |
|---|---|
| Also known as | Ocrelizumab |
| Sponsor | Celltrion |
| Drug class | PD-L1 inhibitor |
| Target | PD-L1 (Programmed Death Ligand 1) |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
CT-P53 is a biosimilar or follow-on biologic targeting PD-L1, a checkpoint protein that tumors use to evade immune surveillance. By blocking PD-L1, the drug releases the brakes on T-cell mediated immunity, allowing the immune system to recognize and attack cancer cells. This mechanism is similar to other PD-L1 inhibitors and is used across multiple solid tumor types.
Approved indications
- Non-small cell lung cancer
- Other solid tumors (under investigation in Phase 3)
Common side effects
- Fatigue
- Decreased appetite
- Nausea
- Immune-related adverse events (pneumonitis, hepatitis, colitis)
Key clinical trials
- Formatting the Risk Prediction Models for Never-Smoking Lung Cancer
- A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis (PHASE3)
- P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC (PHASE2)
- Evaluation of the Diagnostic and Prognostic Role of PET (PET/CT and PET/MRI) in Gynecological Tumors.
- Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer (PHASE2)
- Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer (PHASE2)
- C11 AMT Positron Emission Tomography (PET) Imaging in Patients With Metastatic Invasive Breast Cancer (NA)
- Is There Any Relation Between Serum Anti-p53 Antibody and TLG, MTV and SUV as PET Parameters in Lung Cancer Patients?
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CT-P53 CI brief — competitive landscape report
- CT-P53 updates RSS · CI watch RSS
- Celltrion portfolio CI